BioWorld

Sep. 29, 2006

FDA Clears Amgen's Vectibix, Adds To ImClone's Troubles

Late Wednesday, the FDA approved the next in a growing line of targeted cancer therapies, Amgen Inc.'s Vectibix (panitumumab). (BioWorld Today) Read More

Athenagen Series B Garners $50M For Alzheimer's, AMD

Grant Gives Alnylam $23M For Anti-Ebola Virus Work

Startup Alvine Aims At Celiac Disease, Closes $21M Round

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...